(0.25%) 5 144.25 points
(0.26%) 38 541 points
(0.35%) 17 909 points
(-0.81%) $83.17
(1.25%) $1.947
(-0.07%) $2 345.50
(0.29%) $27.62
(0.89%) $930.30
(-0.27%) $0.932
(-0.29%) $10.99
(-0.38%) $0.797
(0.87%) $92.67
@ $1.160
Utstedt: 14 feb 2024 @ 15:35
Avkastning: -5.17%
Forrige signal: feb 13 - 15:30
Forrige signal:
Avkastning: 0.00 %
Live Chart Being Loaded With Signals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...
Stats | |
---|---|
Dagens volum | 351 535 |
Gjennomsnittsvolum | 1.47M |
Markedsverdi | 192.92M |
EPS | $0 ( 2024-03-05 ) |
Neste inntjeningsdato | ( $-0.0300 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.86 |
ATR14 | $0.00300 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Rojkjaer Lisa | Buy | 187 500 | Employee Stock Option (right to buy) |
2024-03-27 | Rojkjaer Lisa | Buy | 0 | |
2024-02-28 | Schorno Dean L | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Schorno Dean L | Buy | 62 500 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
93.23 |
Last 98 transactions |
Buy: 9 654 000 | Sell: 304 047 |
Volum Korrelasjon
Rigel Pharmaceuticals Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
CRNC | 0.963 |
ROIV | 0.959 |
NLSP | 0.958 |
MLCO | 0.954 |
MOMO | 0.954 |
FXCO | 0.951 |
CTSO | 0.949 |
APAC | 0.948 |
VRDN | 0.946 |
BRAC | 0.945 |
10 Mest negative korrelasjoner | |
---|---|
GRIN | -0.954 |
PIII | -0.939 |
RIVN | -0.938 |
SNPX | -0.925 |
OP | -0.924 |
SWAV | -0.923 |
ZENV | -0.923 |
LAWS | -0.919 |
NAKD | -0.916 |
ENPH | -0.916 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Rigel Pharmaceuticals Inc Korrelasjon - Valuta/Råvare
Rigel Pharmaceuticals Inc Økonomi
Annual | 2023 |
Omsetning: | $116.88M |
Bruttogevinst: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2023 |
Omsetning: | $116.88M |
Bruttogevinst: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2022 |
Omsetning: | $120.24M |
Bruttogevinst: | $118.49M (98.55 %) |
EPS: | $-0.360 |
FY | 2021 |
Omsetning: | $149.24M |
Bruttogevinst: | $148.15M (99.27 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.